Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report.
Obes Facts · 2024
Last updated 2026-05-28A 43-year-old man with extreme obesity (255 kg, BMI 93.7 kg/m²) and severe lymphedema in his left leg lost 40 kg (15.7% of his body weight) after 28 weeks of semaglutide treatment. His lymphedema improved, with a reduction of at least 16 cm in his left thigh circumference, and he regained the ability to walk and perform daily activities. The semaglutide dose started at 1 mg/week but was later reduced to 0.25 mg/week to prevent malnutrition, and nutritional supplements were added.
AI summary of the abstract below.
| Journal | Obes Facts, 2024 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.37 |
| NIH percentile | 23 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
INTRODUCTION: Extreme obesity (BMI ≥50 kg/m2) is a complex pathology to treat. One of the complications of extreme obesity is massive localized lymphedema (MLL), due to compromised lymphatic drainage. There is a lack of literature guiding the medical management of these conditions.
CASE PRESENTATION: We present a 43-year-old male who was admitted to our specialized obesity center for weight management. His initial weight was 255 kg and BMI was 93.7 kg/m2. He suffered from massive multifocal lymphedema of his left leg. He was bedridden due to his condition and malnourished, as shown by multiple vitamin deficiencies. The patient received care from our multidisciplinary team including nurses, dieticians, physical therapists, and psychologists. Treatment with semaglutide was started in hospital and continued at home. The maximal dose used was 1 mg/week but decreased during follow-up to 0.25 mg/week to avoid malnutrition. Protein and nutritional supplements were added. At 28 weeks of therapy, the patient had lost 40 kg or 15.7% of his total body weight. His lymphedema decreased; he had lost at least 16 cm of his left thigh circumference. He was able to walk again and regain autonomy of his daily activities of living.
CONCLUSION: Semaglutide can be effective in patients with extreme obesity, with the support of a multidisciplinary team in a specialized obesity center. It can also help decrease MLL. More data are needed to guide medical treatment of patients with extreme obesity and MLL.
Verbatim abstract via PubMed 39250902 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.